A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants

12 - 64 years of age
Compensation Provided
About the Study
The goal of this study is to test if GS-5245 is safe and effective for the treatment of COVID-19 in participants who have a standard risk of developing severe illness.
What does the study involve?
Participants will receive a tablet (GS-5245 350 mg or a placebo) administered orally without regard to food twice daily for 5 days.
Who can participate?
Participants must be at between 12 and 64 years old, diagnosed with Covid 19 within the last 72 hours, with symptoms.
Where is the study taking place?
The study is being conducted at our Hollywood, Boynton, and Weston offices.
Is compensation provided?
Yes, you will be compensated for your participation. Travel reimbursement and meals are not provided.

Apply for this study

Please enter your name, a valid phone number, and a valid email address where you can be contacted.

More clinical trials at our locations